Gene Modified Immune Cells After Conditioning Regimen for Melanoma or Solid Tumors
Phase 1
18
about 1.1 years
18–75
3 sites in CA
What this study is about
This trial is testing a new treatment using gene-modified immune cells (IL13Ralpha2 CAR T cells) after chemotherapy. The goal is to find the safest dose and see how long these modified cells stay in your body while attacking cancer cells.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Fludeoxyglucose F-18
- 2.Receive IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
- 3.Take Cyclophosphamide
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), Antineoplastic Agent [TC] (Nucleic Acid Synthesis Inhibitors), fludeoxyglucose (18F)
infusion, injection (Injection)
Primary: Dose-limiting toxicity, Incidence of adverse events
Secondary: Complete response (CR), Duration of overall response, Objective response rate, Overall survival, Partial response (PR), Progression-free survival, Time to disease progression
biopsy, diagnostic, imaging
Oncology, Respiratory